ARIA Stock - Buy or Sell?

Ariad Pharmaceuticals Inc. (ARIA) Stock - Buy or Sell?

November 23, 2013 - Shares of Ariad Pharmaceuticals Inc. (ARIA) skyrocketed 36% to $3.78 on Friday after ARIA Announced a Positive Opinion by the European Medicines Agency on the Continued Availability of Iclusig in Patients with Leukaemias.   Shares hit a high of $4.04 before falling into the close.

“We have been working closely with the EMA to provide updated clinical-trial data on patients treated with Iclusig,” said Jonathan E. Dickinson, general manager, ARIAD Pharmaceuticals (Europe). “The conclusions reached by the CHMP, which were announced today, confirm a positive benefit-risk assessment for Iclusig after considering the most recent safety information. We expect that this will provide helpful guidance for patients and healthcare professionals as they consider the treatment options.”

So is it time to buy ARIA?  Biotechnology stocks are very risky so whenever I'm trying to make a decision, I let the charts do that talking.  ARIA stock has resistance at $4.28 & $4.53.  If the stock breaks above this zone of resistance, the stock has the potential to explode.  I will be buying on a break above $4.28 for a trade.

If you would like more trading alerts and want to receive my pre market trading report, join my stock picks group.  Also check out - Top Stocks Gainers 2013 - Top Penny Stock Gainers 2013 - Stock Picks 2014

Ariad ARIA Stock up on Phase 3 Trial - Ridaforolimus

September 14, 2009 - Shares of Ariad Pharmaceuticals Inc. (ARIA) are set to open higher today as the company has come out with positive phase 3 trial data.


ARIAD Announces Result of First Interim Analysis of Phase 3 Succeed Trial of Oral Ridaforolimus, Its Investigational mTOR Inhibitor, in Metastatic Sarcomas

Trial To Continue Enrolling Patients And Proceed To Completion

ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced that the independent Data Monitoring Committee (DMC) of the Phase 3 SUCCEED trial has completed the first interim efficacy analysis as specified by the study protocol and has recommended that the randomized, placebo-controlled trial of oral ridaforolimus in patients with metastatic sarcomas continue to full patient enrollment and completion. The DMC made this recommendation after reviewing the pre-specified statistical analyses and available data on the safety and efficacy of oral ridaforolimus.

The DMC review comprised approximately one-third of the total number of progression-free survival events anticipated in the trial. The safety and efficacy of oral ridaforolimus is being evaluated in patients with metastatic soft-tissue and bone sarcomas who have achieved a favorable response to chemotherapy. The primary end-point of the trial is progression-free survival. Full Article

For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free